These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2412389)

  • 1. Antigens of Pseudomonas aeruginosa and their use in immunoprophylaxis and immunotherapy.
    Stanislavsky ES; Dmitriev BA; Lányi B; Joó I
    Acta Microbiol Hung; 1985; 32(1):3-37. PubMed ID: 2412389
    [No Abstract]   [Full Text] [Related]  

  • 2. [Protective polysaccharide-protein artificial antigens from O-specific polysaccharides of Pseudomonas aeruginosa and its exotoxin A].
    Dmitriev BA; Kul'shin VA; Antsiferova NG; Vovk VA; Moroz AF
    Dokl Akad Nauk SSSR; 1988; 298(5):1277-80. PubMed ID: 2454182
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical and genetic aspects of Pseudomonas aeruginosa virulence.
    Lory S; Tai PC
    Curr Top Microbiol Immunol; 1985; 118():53-69. PubMed ID: 2414071
    [No Abstract]   [Full Text] [Related]  

  • 4. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunoprophylaxis and immunotherapy of infection caused by Pseudomonas aeruginosa: research results and prospects].
    Stanislavskiĭ ES; Joó I
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):22-31. PubMed ID: 6414198
    [No Abstract]   [Full Text] [Related]  

  • 6. A multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase, exotoxin A and a common protective antigen (OEP). Application in patients with diffuse panbronchiolitis.
    Homma JY; Tanimoto H
    Antibiot Chemother (1971); 1987; 39():215-21. PubMed ID: 3118783
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunological study of Pseudomonas aeruginosa extracellular slime.
    Stanislavsky ES; Yushkova NA; Edvabnaya LS; Landsman NM; Zaidner IG
    Acta Microbiol Hung; 1985; 32(1):49-59. PubMed ID: 2412390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
    Pier GB
    Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylaxis of Pseudomonas aeruginosa infections in leukopenic mice by a combination of active and passive immunization.
    Martinez D; Callahan LT
    Eur J Clin Microbiol; 1985 Apr; 4(2):186-9. PubMed ID: 3924606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined host and specific anti-Pseudomonas-directed therapy for Pseudomonas aeruginosa infections in burned mice: experimental results and theoretic considerations.
    Holder IA; Neely AN
    J Burn Care Rehabil; 1989; 10(2):131-7. PubMed ID: 2496130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pathogenesis of infections owing to Pseudomonas aeruginosa using the burned mouse model: experimental studies from the Shriners Burns Institute, Cincinnati.
    Holder IA
    Can J Microbiol; 1985 Apr; 31(4):393-402. PubMed ID: 3924388
    [No Abstract]   [Full Text] [Related]  

  • 12. Slime glycolipoproteins and the pathogenicity of various strains of Pseudomonas aeruginosa in experimental infection.
    Dimitracopoulos G; Bartell PF
    Infect Immun; 1980 Nov; 30(2):402-8. PubMed ID: 6777303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
    Montie TC; Drake D; Sellin H; Slater O; Edmonds S
    Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785
    [No Abstract]   [Full Text] [Related]  

  • 14. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
    Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
    Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of Pseudomonas aeruginosa infections].
    Cotar AI
    Bacteriol Virusol Parazitol Epidemiol; 2009; 54(4):139-45. PubMed ID: 20923118
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Lang A; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Schaad U
    Behring Inst Mitt; 1997 Feb; (98):345-9. PubMed ID: 9382759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.
    Holder IA; Wheeler R; Montie TC
    Infect Immun; 1982 Jan; 35(1):276-80. PubMed ID: 6797948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Virulence and the antigens of Pseudomonas aeruginosa].
    Stanislavskiĭ ES; Kolker II
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Jul; (7):16-23. PubMed ID: 112806
    [No Abstract]   [Full Text] [Related]  

  • 19. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations.
    Holder IA; Naglich JG
    J Trauma; 1986 Feb; 26(2):118-22. PubMed ID: 2418208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
    Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
    Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.